<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107922</url>
  </required_header>
  <id_info>
    <org_study_id>P-20180016364</org_study_id>
    <nct_id>NCT04107922</nct_id>
  </id_info>
  <brief_title>Nutraceutical on Hyperglycemia</brief_title>
  <official_title>Metabolic Actions of a Supplement of Ilex Paraguariensis, White Mulberry and Chromium Picolinate in Non-diabetic Subjects With Dysglycemia, a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim will be to evaluate if Glicoset速 1000, a nutraceutical containing Ilex
      Paraguariensis, White Mulberry and Chromium Picolinate, can be effective in improving
      glycemic status in subject with dysglycemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim will be to evaluate if Glicoset速 1000, a nutraceutical containing Ilex
      Paraguariensis, White Mulberry and Chromium Picolinate, can be effective in improving
      glycemic status in subject with dysglycemia.

      The investigators will enroll patients with impaired fasting plasma glucose (IFG) or impaired
      glucose tolerance (IGT), not taking hypoglycemic agents (both pharmaceuticals or
      nutraceutical agents). Patients will be randomized to take placebo or Glicoset速 1000 for 3
      months, in a randomized, double-blind, placebo-controlled design. Glicoset速 1000 and placebo
      will be self-administered once a day, 1 tablet during the breakfast.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of dysglicemia</measure>
    <time_frame>3 months</time_frame>
    <description>Oral glucose tolerance test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Dysglycemia</condition>
  <arm_group>
    <arm_group_label>Glicoset</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glicoset is a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glicoset</intervention_name>
    <description>Patients will take a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate</description>
    <arm_group_label>Glicoset</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will take placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with impaired fasting glucose (IFG) or impaired fasting glucose (IGT)

          -  Patients not taking hypoglycemic agents (both pharmaceuticals or nutraceutical agents)

        Exclusion Criteria:

          -  Patients with type 1 or type 2 diabetes mellitus

          -  Patients with impaired hepatic function

          -  Patient with impaired renal function

          -  Patients with gastrointestinal disorders

          -  Patients with current or previous evidence of ischemic heart disease, heart failure,
             or stroke

          -  Patients with weight change of &gt; 3 Kg during the preceding 3 months

          -  Patients with hystory of malignancy, and significant neurological or psychiatric
             disturbances, including alcohol or drug abuse.

          -  Patients taking (within the previous 3 months) hypoglycemic agents, laxatives,
             beta-agonists (other than inhalers), cyproheptadine, anti-depressants,
             antiserotoninergics, phenothiazines, barbiturates, oral corticosteroids, and
             antipsychotics

          -  Women who were pregnant or breastfeeding or of childbearing potential and not taking
             adequate contraceptive precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>Lombardy</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pavia</investigator_affiliation>
    <investigator_full_name>Giuseppe Derosa</investigator_full_name>
    <investigator_title>MD, PhD, FESC</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

